C4X Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.04 - €0.93
Previous CloseN/A
Volume0.00
Average Volume (3M)5.17K
Market Cap
€349.02M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta0.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume0
30 Day Avg. Volume5,166
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 40.6% revenue rebound to ~€2.6M in 2025 reflects renewed commercial traction or milestone receipts that materially improve operating leverage. Sustained top-line growth supports longer-term R&D funding needs and reduces reliance on dilutive financing if the trend continues.
Strong Gross MarginsGross margins near 67–71% indicate a scalable small-molecule biotech model with relatively low COGS versus revenue. High product-level margins help convert incremental revenue into operating cash and provide durable upside to profitability as development expenses normalize.
Positive Operating & Free Cash FlowOperating cash flow turning positive (~€1.8M) and positive free cash flow (~€0.5M) in 2025 reverses prior cash burn. Improved cash generation enhances runway, lowers near-term refinancing need, and provides a more stable base to fund clinical programs without immediate external capital.
Bears Say
Elevated LeverageA debt-to-equity ratio around 3.7x signals high leverage that constrains financial flexibility. Elevated debt increases interest and covenant risk, raising the likelihood the company must prioritize cash for servicing debt over R&D investment or face costly refinancing if revenue momentum stalls.
Ongoing Net LossesDespite improving CFO, a ~€4.9M net loss in 2025 shows core profitability remains unachieved. Persistent losses mean the company may still need external capital for sustained development spending, which can dilute shareholders or increase leverage if cash generation is not steadily sustained.
Balance-sheet Volatility / Equity InstabilityEquity moving from positive to negative and back to modest positive signals prior dilution, volatility in capital structure, and potential historical reliance on equity/debt raises. This pattern can increase future financing costs and reduce investor confidence when raising non-dilutive or equity capital.
C4X FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.04 and its highest was €0.93 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €349.02M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in DE:C4X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―